BD1
Director Trades
| Date | Director | Value |
|---|
Company News
BARD1 Life Sciences’ licenced SubB2M technology has ‘exquisite specificity’ in detecting ovarian cancer
BARD1 Life Sciences (ASX: BD1) has unveiled “outstanding” preliminary test results showing its licenced SubB2M technology was a 100% specific in detecting all stages of ovarian cancer. Griffith University’s Institute of Glycomics has released data showing SubB2M can be used to detect all ovarian cancer stages with 100% specificity and 100% sensitivity. BARD1 holds the […]
Bard1 Life Sciences and Sienna Cancer Diagnostics announce $23.7m merger
Medical technology companies Bard1 Life Sciences (ASX: BD1) and Sienna Cancer Diagnostics (ASX: SDX) will stage a $23.7 million merger to create an Australian-based cancer diagnostics entity focused on addressing unmet needs in early cancer detection. Under the terms of the agreement, Bard1 will acquire 100% of Sienna’s issued share capital by offering Sienna shareholders […]
BARD1 develops world-first blood test for breast cancer detection; offers high diagnostic accuracy
Perth-based biotech company BARD1 Life Sciences (ASX: BD1) has developed a world-first blood test for the early detection of breast cancer, claiming high diagnostic accuracy and the ability to distinguish between malignant and benign lesions. The breakthrough BARD1 BC test – which uses the same diagnostic platform as the company’s ovarian cancer screening test – […]
BARD1 Life Sciences’ ovarian cancer test detects disease in high-risk women
BARD1 Life Sciences (ASX: BD1) has validated the commercial potential of its ovarian cancer screening test after new research revealed the test’s accuracy in detecting the disease in high-risk women. The new study shows the BARD1-Ovarian screening test has a high accuracy in determining ovarian cancer in women who or are carrying the BRCA1/2 mutations, […]
BARD1 Life Sciences en route to delivering better ovarian cancer screening
BARD1 Life Sciences (ASX: BD1), a biotechnology company developing a non-invasive cancer diagnostics test for ovarian cancer, announced encouraging results today from an improved BARD1-Ovarian test that demonstrated “excellent diagnostic accuracy” of AUC 0.95, 88% sensitivity and 93% specificity for detection of ovarian cancer in test sets. The company has previously established high accuracy rates in detecting […]
BARD1 leverages ProcartaPlex technology to accelerate development of ovarian cancer detection
Australian biotech company BARD1 Life Sciences (ASX: BD1) has entered into an assay development agreement with Thermo Fisher Scientific for custom research assay development of a multiplex autoantibody test system aimed at better detection of ovarian cancer. According to BARD1, the agreement defines the development of a multiplex immunoassay in kit format for the detection […]
BARD1 Life Sciences expands success in non-invasive ovarian cancer test, moves to commercialisation
BARD1 Life Sciences (ASX: BD1) has pronounced additional success for its BARD1-Ovarian test after an independent test confirmed the non-invasive diagnostic tool’s “high accuracy” in detecting ovarian cancer. The follow-on independent OC-400V study evaluated the strength of the BARD1-Ovarian algorithm on 82 ovarian cancers and 27 healthy controls. In this latest study, “high accuracy” in […]
BARD1 Life Sciences receives timely Japanese patent
Australian biotech company BARD1 Life Sciences (ASX: BD1) has been granted an important patent for cancer diagnostics in Japan. The Japan Patent Office issued Japanese Patent number P6271636, titled “BARD1 isoforms in lung and colorectal cancer and use thereof” on 12 January with BARD1 reporting the milestone earlier today. The news means BARD1 is making progress […]
BARD1 reports success in non-invasive ovarian cancer detection study
Biotech stock BARD1 Life Sciences (ASX: BD1) has achieved positive results in its non-invasive ovarian cancer diagnostic study. The OC-400 study revealed the company’s BARD1-Ovarian test yielded high accuracy in detecting ovarian cancer with an average area under the curve of 82% sensitivity and 79% specificity in the test sets. BARD1-Ovarian is a ELISA-based blood […]
Company Videos
No videos found.